ESCLEROSIS MÚLTIPLE
![Foto de ESCLEROSIS MÚLTIPLE](/img/grupo.png)
![Foto de Hospital Universitario Marqués de Valdecilla](/img/noimage_org.png)
Hospital Universitario Marqués de Valdecilla
Santander, EspañaPublications en collaboration avec des chercheurs de Hospital Universitario Marqués de Valdecilla (10)
2024
-
Clinical characteristics and impact on patient-reported outcomes and quality of life of people with ambulatory secondary progressive multiple sclerosis: Discover study
Multiple Sclerosis and Related Disorders, Vol. 90
-
Corrigendum to “Recommendations for the use of anti-dsDNA autoantibodies in the diagnosis and follow-up of systemic lupus erythematosus – A proposal from an expert panel” [Autoimmunity Reviews, Volume 22, Issue 12, December 2023, 103479] (Autoimmunity Reviews (2023) 22(12), (S1568997223002136), (10.1016/j.autrev.2023.103479))
Autoimmunity Reviews
2023
-
Effectiveness and Safety of Teriflunomide in Relapsing–Remitting Multiple Sclerosis and Improvements in Quality of Life: Results from the Real-World TERICARE Study
Neurology and Therapy, Vol. 12, Núm. 6, pp. 2177-2193
-
Laboratory and clinical practices in antinuclear antibody detection and related antigens: recommendations from a Spanish multicentre survey
Immunologic Research, Vol. 71, Núm. 5, pp. 749-759
-
Recommendations for the use of anti-dsDNA autoantibodies in the diagnosis and follow-up of systemic lupus erythematosus – A proposal from an expert panel
Autoimmunity Reviews, Vol. 22, Núm. 12
2021
-
The age again in the eye of the COVID-19 storm: evidence-based decision making
Immunity and Ageing, Vol. 18, Núm. 1
2020
-
COVID-19: Age, Interleukin-6, C-reactive protein, and lymphocytes as key clues from a multicentre retrospective study
Immunity and Ageing, Vol. 17, Núm. 1
2019
-
Multi-centre validation of a flow cytometry method to identify optimal responders to interferon-beta in multiple sclerosis
Clinica Chimica Acta, Vol. 488, pp. 135-142
2015
-
Lipid-specific immunoglobulin M bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab
Annals of Neurology, Vol. 77, Núm. 3, pp. 447-457